Eterna Therapeutics is a biotech company focused on the development of off-the-shelf cellular therapies using mRNA-based technology and induced pluripotent stem cells (iPSCs). The company's platform ...
Researchers in Australia have reprogrammed the RNA-cutting enzyme PspCas13b to destroy the fusion transcripts that drive many ...
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today ...
The ISSCR iPSC 20th Anniversary Symposium convenes the global stem cell community in Kyoto, the birthplace of iPSCs, to mark ...
Tuesday, November 3rd at 11:00am EST / 5:00pm CET Genome Safety Webinar Series: Regulatory Expectations, Practical Workflows, ...
With CRISPR/Cas9 moving from a research tool into adaption as personalized medicine, safety concerns have to be addressed: an understanding of the effects on the targeted gene, but also potential ...
Wave Life Sciences has reached alignment with the US Food and Drug Administration on a registrational pathway for WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin ...
Six patients with glycogen storage disease type Ia have received a single infusion of BEAM-301, an in vivo base editor designed to correct the R83C variant in G6PC1. Both evaluable patients in the ...
The annual list honors the world’s boldest and brightest new ideas that are making the world better — each invention has been chosen for its originality, effectiveness, ambition, and real-world impact ...
A Danish team has used prime editing to repair a disease-causing GATA2 deletion in patient-derived blood stem and progenitor cells without making a DNA double-strand break. In mice, the edited cells ...
Researchers have used CRISPR-Cas9 to remove CD28 from donor T cells and prevent fratricide before equipping them with CD28-targeting CARs. In preclinical T-cell acute lymphoblastic leukemia (T-ALL) ...
Researchers built a three-layer human blood-vessel model that shows how fibroblasts amplify the vascular pathology of Hutchinson-Gilford progeria syndrome (HGPS). Correcting the disease-causing LMNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results